Zygomycosis Nasal Congestion

What is Zygomycosis Nasal Congestion?

Zygomycosis (also called mucormycosis) is a rare but serious fungal infection caused by molds in the order Mucorales. When these organisms invade the nasal passages and sinus cavities, they can cause severe nasal congestion, facial pain, and tissue necrosis. The condition is most often referred to as rhinocerebral mucormycosis. Because the fungi grow rapidly and can spread to the orbit and brain, early recognition and treatment are critical.

The infection usually begins after inhalation of fungal spores that settle in the nasal mucosa. In healthy individuals the immune system clears these spores without incident. However, in people with weakened immune defenses, the fungi can proliferate, leading to inflammation, blockage, and, in advanced cases, tissue destruction.

Sources: Mayo Clinic; CDC; NIH National Institute of Allergy and Infectious Diseases (NIAID).

Common Causes

Many underlying conditions increase the risk of developing zygomycosis‑related nasal congestion. The most frequent contributors include:

• Uncontrolled diabetes mellitus (especially diabetic ketoacidosis)
• Hematologic malignancies such as leukemia or lymphoma
• Solid‑organ or stem‑cell transplantation with immunosuppressive therapy
• Prolonged corticosteroid use (e.g., for asthma, autoimmune disease)
• Neutropenia (low neutrophil count) from chemotherapy or bone‑marrow failure
• Severe trauma or burns that disrupt the nasal mucosa
• Iron overload or deferoxamine therapy – iron is a growth factor for Mucorales
• Chronic nasal or sinus disease (e.g., allergic fungal sinusitis) that damages mucosal barriers
• Environmental exposure to high concentrations of spores (construction sites, decaying organic material)
• Malnutrition or chronic kidney disease that impairs immune function

Even individuals without obvious risk factors can develop the infection after traumatic facial injuries or inhalation of a large spore load.

Associated Symptoms

When zygomycosis involves the nasal cavity, the congestion is usually accompanied by other warning signs:

• Profound nasal blockage on one side
• Purulent or bloody nasal discharge
• Facial pain, tenderness, or swelling, especially over the cheekbones or around the eyes
• Black or necrotic tissue (eschar) inside the nostrils or on the palate
• Fever and chills
• Headache that may be localized to the sinus region
• Visual disturbances – double vision, loss of vision, or eye swelling
• Dental pain or loose upper teeth (indicating spread to the maxilla)
• Altered mental status or seizures if the infection spreads to the brain

These symptoms can progress quickly; many patients notice worsening over a few days.

When to See a Doctor

The following situations warrant prompt medical evaluation:

• Sudden, severe nasal congestion that does not improve with over‑the‑counter decongestants.
• Facial pain or swelling that is rapidly worsening.
• Any black, ulcerated, or necrotic tissue visible inside the nose or mouth.
• Fever ≥38°C (100.4°F) combined with sinus symptoms.
• Vision changes (blurred vision, double vision, eye pain, or loss of sight).
• Neurologic symptoms such as severe headache, confusion, or seizures.
• History of diabetes, cancer, recent transplant, or prolonged steroid use with any of the above signs.

Because rhinocerebral mucormycosis can advance to life‑threatening complications within 24–48 hours, early medical attention is essential.

Diagnosis

Diagnosing zygomycosis nasal congestion requires a combination of clinical suspicion and targeted investigations.

1. Clinical Examination

• Detailed otolaryngologic (ENT) exam with nasal endoscopy to visualize mucosa, discharge, and any necrotic tissue.
• Inspection for orbital involvement (proptosis, ophthalmoplegia) and neurologic deficits.

2. Imaging Studies

• CT scan of the sinuses – shows bony erosion, sinus opacification, and extent of disease.
• MRI with contrast – superior for detecting soft‑tissue invasion, orbital extension, and intracranial spread.

3. Laboratory Tests

• Complete blood count (CBC) and metabolic panel to assess for diabetes, neutropenia, and renal function.
• Serum glucose and ketone testing in diabetics.
• Fungal cultures or PCR from nasal tissue; however, cultures are often negative, so tissue biopsy is preferred.

4. Histopathology

The gold standard is a biopsy of the suspicious tissue examined under a microscope. Characteristic findings include broad, non‑septate (or sparsely septate) hyphae that branch at right angles and demonstrate angioinvasion (invasion of blood vessels), leading to tissue necrosis.

5. Additional Tests (if indicated)

• Serum iron studies if deferoxamine therapy is suspected.
• Blood cultures when systemic spread is a concern.

Treatment Options

Management of rhinocerebral mucormycosis requires an aggressive, multimodal approach.

Medical Therapy

• First‑line antifungal: Intravenous liposomal amphotericin B (5–10 mg/kg/day). Liposomal formulation reduces nephrotoxicity.
• If amphotericin B is contraindicated or as step‑down therapy: Posaconazole or Isavuconazole** (both oral and IV options).
• Duration: Typically 6–8 weeks of IV therapy, followed by oral azole therapy for several months, guided by clinical and radiologic response.
• Adjunctive measures: Tight glycemic control, correction of acidosis, and discontinuation of immunosuppressive agents when feasible.

Surgical Management

Early and extensive surgical debridement is crucial because antifungal agents poorly penetrate necrotic tissue.

• Endoscopic sinus surgery to remove infected mucosa and bone.
• Open procedures (Caldwell‑Luc, craniofacial resection) if disease extends beyond the sinuses.
• Repeated debridements are often needed until all necrotic tissue is cleared.

Supportive & Home Care

• Maintain optimal hydration and nutrition.
• Use saline nasal irrigations (isotonic or hypertonic) to keep nasal passages moist—only after ENT clearance.
• Control blood glucose with insulin regimens; monitor ketones daily if diabetic.
• Avoid exposure to dusty or mold‑laden environments during recovery.

Follow‑Up

Patients require regular ENT and infectious‑disease follow‑up, repeat imaging at 2‑4 weeks, and long‑term monitoring for recurrence for at least 1 year.

Prevention Tips

Because most cases occur in individuals with compromised immunity, prevention focuses on reducing exposure and optimizing host defenses.

• Strict control of blood sugar levels; aim for HbA1c <7 % (individualized).
• Prompt treatment of diabetic ketoacidosis.
• Limit use of systemic corticosteroids to the lowest effective dose and duration.
• Monitor neutrophil counts in chemotherapy patients; use growth‑factor support if indicated.
• Avoid eating foods stored in warm, humid conditions that can harbor molds.
• Wear N95 or equivalent respiratory protection when working in construction sites, farms, or compost facilities.
• Maintain good nasal hygiene; regular saline rinses can help clear spores in high‑risk environments (after physician approval).
• For patients on deferoxamine, consider alternative iron chelators (e.g., deferasirox) that do not feed the fungus.
• Educate caregivers and patients about early signs – especially facial pain, black nasal discharge, or vision changes.

Emergency Warning Signs

Key Take‑aways

Zygomycosis presenting as nasal congestion is a medical emergency for anyone with risk factors such as uncontrolled diabetes, immunosuppression, or recent trauma. The infection progresses quickly, often causing tissue death and can spread to the eyes and brain. Early diagnosis through endoscopic examination, imaging, and biopsy, combined with aggressive antifungal therapy and surgical debridement, offers the best chance for survival. Preventive measures focus on controlling underlying diseases, minimizing exposure to fungal spores, and maintaining good nasal hygiene.

References:

1. Mayo Clinic. “Mucormycosis (black fungus)”. Accessed March 2024.
2. Centers for Disease Control and Prevention. “Mucormycosis”. Updated 2023.
3. NIH National Institute of Allergy and Infectious Diseases. “Fungal Infections”. 2022.
4. Cleveland Clinic. “Rhinocerebral Mucormycosis”. 2023.
5. World Health Organization. “Guidelines for the Diagnosis and Management of Mucormycosis”. 2021.